Stock Performance Review on Biotech Industry -- Vertex Pharma, Axovant Sciences, Cerecor, and Ocular Therapeutix

Thursday, September 28, 2017 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, September 28, 2017 /PRNewswire/ --

If you want a Stock Review on VRTX, AXON, CERC, or OCUL then come over

to and sign up for your free customized report today. On Wednesday, the NASDAQ Composite ended the day at 6,453.26, up 1.15%; the Dow Jones Industrial Average edged 0.25% higher, to finish at 22,340.71; and
the S&P 500 closed at 2,507.04, marginally gaining 0.41%. Gains were broad based as six out of nine sectors finished the trading session in green. has initiated research reports on the following Biotechnology stocks: Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Axovant Sciences Ltd (NASDAQ: AXON), Cerecor Inc. (NASDAQ: CERC), and Ocular Therapeutix Inc. (NASDAQ: OCUL). Daily Stock Tracker published comprehensive and free research reports on these stocks today at:

Vertex Pharmaceuticals 

Boston, Massachusetts headquartered Vertex Pharmaceuticals Inc.'s stock finished Wednesday's session 0.41% higher at $149.07. A total volume of 2.10 million shares was traded, which was above its three months average volume of 1.81 million shares. The stock has gained 13.70% over the past three months, 67.27% in the previous twelve months, and 102.35% since the start of this year. The Company's shares are trading above their 200-day moving average by 28.48%. Moreover, shares of Vertex Pharma, which discovers, develops, manufactures, and commercializes medicines for serious diseases, have a Relative Strength Index (RSI) of 38.61.

On September 15th, 2017, research firm RBC Capital Markets initiated an 'Outperform' rating on the Company's stock, with a target price of $175 per share. VRTX complete research report is just a click away and free at:

Axovant Sciences 

Shares in London, the UK-based Axovant Sciences Ltd rose 10.43%, ending yesterday's session at $6.99. A total volume of 11.94 million shares was traded, which was above its three months average volume of 1.28 million shares. The Company's shares are trading below their 50-day moving average by 67.53%. Moreover, shares of Axovant Sciences, which engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the US and Europe, have an RSI of 23.41.

On September 27th, 2017, research firm Robert W. Baird downgraded the Company's stock rating from 'Outperform' to 'Neutral' while revising its previous target price from $29 a share to $6 a share. The complimentary report on AXON can be downloaded at:


On Wednesday, US-based Cerecor Inc.'s stock saw a rise of 1.26%, to close the day at $0.81. A total volume of 161,808 shares was traded. The Company's shares have advanced 14.05% in the last one month and 42.73% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 13.09% and 9.99%, respectively. Additionally, shares of Cerecor, which develops treatments for patients suffering from nervous system disorders, have an RSI of 58.80. Sign up for your complimentary research report on CERC at:

Ocular Therapeutix 

Shares in Bedford, Massachusetts headquartered Ocular Therapeutix Inc. ended the day 0.63% higher at $6.43. A total volume of 340,107 shares was traded. The stock has gained 12.61% in the last one month. The Company's shares are trading above their 50-day moving average by 3.74%. Furthermore, shares of Ocular Therapeutix, which focuses on the development, manufacture, and commercialization of ocular therapies using its Hydrogel technology, have an RSI of 53.46. Get free access to your research report on OCUL at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: (207) 331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store